Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Lactobacillus brevis is a probiotic bacterium that has been investigated for its potential role in supporting urinary tract health, including the prevention of urinary tract infections (UTIs). The primary rationale for using Lactobacillus species (including L. brevis) in UTI prevention is their ability to colonize the urogenital tract and inhibit the growth of uropathogens such as Escherichia coli through mechanisms like competitive exclusion, production of lactic acid, and modulation of the immune response.

However, most of the research and clinical evidence supporting probiotics for UTI prevention has focused on other Lactobacillus species, particularly L. crispatus, L. rhamnosus, and L. reuteri. There are only limited studies specifically investigating L. brevis for UTIs. Some in vitro and animal studies suggest that L. brevis can inhibit uropathogens, but high-quality human clinical trials demonstrating a clear benefit for UTI prevention or treatment are lacking.

In summary, while the use of L. brevis for UTIs has some scientific plausibility based on its probiotic properties and limited laboratory data, there is only weak clinical evidence directly supporting its effectiveness for this condition. Therefore, the evidence rating is 2 out of 5, reflecting a foundation of preliminary research but a lack of robust, targeted clinical studies.

More about Lactobacillus brevis
More about Urinary Tract Infections

Other ingredients used for Urinary Tract Infections

Other health conditions supported by Lactobacillus brevis

Products containing Lactobacillus brevis

Douglas Laboratories Multi-Probiotic ® 40 Billion
Douglas Laboratories Multi-Probiotic ® 40 Billion